Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 4/20 | 0.45 |
| ▸ | BIRC2 | Q13490 | 10/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 8/20 | 0.40 |
| ▸ | BIRC3 | Q13489 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22450599 | 1.00 | TNF (0.45) | TNFBIRC2CYP3A4XIAPBIRC3 | |
| SCHEMBL22450830 | 1.00 | TNF (0.45) | TNFBIRC2CYP3A4XIAPBIRC3 | |
| SCHEMBL24067369 | 0.88 | TNF (0.46) | TNFBIRC2CYP3A4XIAPBIRC3 | |
| SCHEMBL24067357 | 0.88 | TNF (0.46) | TNFBIRC2CYP3A4XIAPBIRC3 | |
| SCHEMBL24067367 | 0.87 | BIRC2 (0.45) | TNFBIRC2CYP3A4XIAPBIRC3 | |
| SCHEMBL22450668 | 0.87 | BIRC2 (0.45) | TNFBIRC2CYP3A4XIAPBIRC3 | |
| SCHEMBL24067411 | 0.81 | CNR1 (0.46) | TNFBIRC2CYP3A4XIAPBIRC3 | |
| SCHEMBL22450712 | 0.81 | CNR1 (0.46) | TNFBIRC2CYP3A4XIAPBIRC3 | |
| SCHEMBL24067338 | 0.80 | TNF (0.54) | TNFBIRC2CYP3A4XIAPBIRC3 | |
| SCHEMBL24182128 | 0.80 | TNF (0.47) | TNFBIRC2CYP3A4XIAPBIRC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175917-A1 | COMBINATION OF IAP INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | BIRC5, XIAP, BIRC2 | TNF 1106/4885BIRC2 3/4885CYP3A4 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.